

# AVITA MEDICAL, INC.

## INSIDER TRADING AND SECURITIES DEALING POLICY

### INTRODUCTION

In the course of performing your duties for AVITA Medical, Inc. (“AVITA Medical”) or its subsidiaries or affiliates (collectively, the “**Group**”), you may, at times, have information about AVITA Medical or another publicly traded company that the Group has relationships with that is not generally available to the public. AVITA Medical has its securities listed on both The Nasdaq Stock Market (“**Nasdaq**”) in the United States and also the Australian Securities Exchange (“**ASX**”) in Australia, and as a result AVITA Medical, as well as all “Restricted Persons” (defined below) must comply with certain United States federal and state securities laws as well as the Corporations Act of Australia, which collectively prohibit you from trading, or procuring another person to trade, in AVITA Medical securities on the basis of such information or providing that information to others who may trade on the basis of such information.

This Insider Trading and Securities Dealing Policy (this “**Policy**”) outlines the conditions under which you may conduct transactions in AVITA Medical securities [and in the securities of other companies with which the Group has relationships or whose securities may be impacted by the Group or non-public information obtained regarding the Group (“**Related Entities**”) (e.g., with which AVITA Medical conducts business or are competitors in AVITA Medical’s industry)].

This Policy seeks to explain some of your obligations to the Group and under the law, to prevent actual, or the appearance of, insider trading and to protect the Group’s reputation for integrity and ethical conduct.

**It is your obligation to understand and comply with this Policy.**

Should you have any questions regarding this Policy, please contact AVITA Medical’s General Counsel, Donna Shiroma, at [dshiroma@avitamedical.com](mailto:dshiroma@avitamedical.com).

This Policy applies globally and has been approved by the Board of Directors of AVITA Medical (the “**Board**”). The Policy will be reviewed and re-approved on a regular basis and, as part of the Board’s review process, this Policy is updated as required to reflect appropriate legal and regulatory changes. The Appendices to this Policy summarize certain provisions of Australian and U.S. laws that apply to you.

### PERSONS TO WHOM THIS POLICY APPLIES

This Policy extends to all directors, officers and employees of the Group, as well as any consultants, contractors or other individuals retained by the Group who are designated as “insiders” by AVITA Medical. Additionally, this Policy extends to family members or anyone else residing in your household and any family members, not otherwise residing in your household, whose transactions in securities are directed by you or are subject to your influence or control (e.g., your parents or children). This Policy also applies to any entities that you or other persons who you have a relationship with may influence or control,

including any corporations, partnerships or trusts (charitable or otherwise). All of the above persons or entities are collectively referred to as “**Restricted Persons**”.

You are responsible for the transactions conducted by your family members and other affiliated persons or entities and should make them aware of their obligations under this Policy. Transactions by your family members and other persons or entities subject to this Policy are treated for the purpose of this Policy as if they were undertaken by you or for your benefit. Accordingly, all references to you with regard to trading restrictions or pre-clearance procedures in this Policy also apply to your family members or other persons or entities with whom you have a relationship that are subject to this Policy.

## **TRANSACTIONS COVERED BY THIS POLICY**

AVITA Medical is a company incorporated under the laws of the State of Delaware in the United States and it has listed its shares of common stock for trading on the Nasdaq. In addition, AVITA Medical’s CHES Depositary Interests (CDIs), being units of beneficial ownership in AVITA Medical’s underlying shares of common stock, are listed on the ASX.

Transactions covered by this Policy include purchases and sales of shares of common stock, CDIs, any derivatives securities (such as put or call options) and any debt or other equity securities issued in the future by AVITA Medical. Trading also includes certain transactions under Group equity plans.

## **MATERIAL NON-PUBLIC INFORMATION**

This Policy is designed to prevent illegal trading in securities while you possess material non-public information. Determining what information is “material” and “inside” at any given time can be difficult. “Material” information is that which would be considered important by reasonable investors in deciding whether to buy, sell or hold the securities in question. Information generally would be considered material if it concerns earnings estimates, significant merger or acquisition proposals or agreements, proposed increases or decreases in dividends, stock splits, significant expansion or curtailment of operations, extraordinary borrowing, liquidity or litigation problems, important management changes, research developments or any other important developments, trends or uncertainties which may have an impact on AVITA Medical. Regulators will scrutinize a questionable trade after the fact with the benefit of hindsight, so it is best always to err on the side of deciding that the information is material and not trade if in doubt. **If you are unsure whether information is material, you should either consult the General Counsel before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates or assume that the information is material.**

The standard for assessing whether information is “inside” or non-public, is whether the information is generally available to the public. Information generally could be considered to be available to the public when it has been released to the public through appropriate channels (i.e., public regulatory filings, by means of an official press release or a statement from one of AVITA Medical's senior officers or designated spokespersons), and enough time has elapsed to permit the market to absorb and evaluate the information. As a general rule, without limiting other provisions of the Policy, you should consider information to be nonpublic until at least two full trading days have elapsed following public disclosure. All directors, officers, employees and consultants must maintain the confidentiality of AVITA

Medical information for competitive, security and other business reasons, as well as to comply with securities laws. All information about AVITA Medical or its business plans is potentially nonpublic information until it is publicly disclosed. **As with questions of materiality, if you are not sure whether information is considered public, you should either consult with the General Counsel or assume that the information is nonpublic and treat it as confidential.**

Note that the above description of material non-public information is based on applicable U.S. law. For a discussion of the concept under Australian law, please see Appendix 1 to this Policy.

## **PROHIBITION ON TRADING OR TIPPING OF MATERIAL NON-PUBLIC INFORMATION**

While in possession of material non-public information, you are prohibited from buying or selling any AVITA Medical securities or engaging in any other direct or indirect actions to take advantage of material non-public information, or from procuring another person to do so. This is true even if it will cause negative personal consequences (e.g., foregoing gains) or was planned before learning of material, non-public information. This prohibition applies to both securities purchases and securities sales, regardless of how or from whom the material non-public information was obtained and continues to apply post-employment until the information becomes public or non-material. You are also prohibited from disclosing material non-public information to others who might use it for trading or might pass it along to others who might trade (referred to as “tipping”). This includes family members or any other person with whom you have a pattern of sharing confidences, but can include strangers. You should keep non-public information in utmost confidence.

There are no exceptions to this general prohibition. Transactions that may be necessary or justifiable for an independent reason (e.g., raising money for a charity or an emergency) or small transactions are not excepted. This prohibition also applies to material non-public information relating to other publicly traded companies, including Group customers and suppliers. You should treat material non-public information about the Group’s business partners with the same level of care required with respect information related to the Group. Information that is not material to the Group may nevertheless be material to the other entity.

## **PROHIBITION ON SHORT SELLING, HEDGING TRANSACTIONS AND SHORT-TERM TRADING**

Short sales of stock are transactions involving the borrowing of stock, selling it, and then buying stock at a later date to replace the borrowed shares. Short sales generally evidence an expectation on the part of the seller that the securities will decline in value and have the potential to signal to the market a lack of confidence in the company. Consequently, short sales of AVITA Medical securities are prohibited. Similarly, you are prohibited from purchasing or using, directly or indirectly, financial instruments (e.g., swaps, collars, forward contracts, etc.) that are designed to hedge or offset any decrease in the market value of AVITA Medical securities, including both vested and unvested securities.

Short-term trading of AVITA Medical’s securities can create a focus on our short-term stock market performance instead of promoting the Group’s long-term business objectives. For these reasons, Designated Persons (as defined herein) who purchase (or sell) AVITA Medical

securities in the open market may not sell (or purchase) any AVITA Medical securities of the same class during the six months following the transaction.

## **PRE-CLEARANCE ON USE OF MARGIN ACCOUNTS AND PLEDGING OF SECURITIES**

If your AVITA Medical securities are held in a margin account or pledged as collateral, they may be sold without your consent under certain circumstances. As a result, a margin or foreclosure sale of AVITA Medical securities could occur when you are otherwise in possession of material, non-public information. Consequently, to the extent you desire to enter into a margin trading or pledging arrangement involving AVITA Medical securities, you must first obtain pre-clearance from the General Counsel.

## **PROHIBITION ON TRADING OUTSIDE OF DESIGNATED OPEN WINDOW PERIODS**

Trading in AVITA Medical securities by you may only occur during the designated open window periods. AVITA Medical has four routine open window periods commencing two Nasdaq trading days following the release of AVITA Medical's annual or quarterly earnings and continuing until the close of trading on the last day of AVITA Medical's quarter. AVITA Medical has the right to modify an open window period at any time and for any reason or may decide that a trading window should not be opened at all during any quarter. The Board in its sole discretion may approve additional open window periods from time to time. For the avoidance of doubt, no person covered by this Policy is permitted to trade or otherwise conduct transactions in AVITA Medical securities outside of the designated open window periods. Moreover, you should note that consummating transactions in AVITA Medical securities, even during an open window period, does not protect you from insider trading violations if you are trading while otherwise in possession of material, non-public information. Consequently, you should use good judgment at all times regarding information you may possess. To the extent you have any questions regarding the nature or timing of the open window periods or the application of this policy to your particular situation, please contact AVITA Medical's General Counsel.

In addition to the above, if you are a director, an executive officer, or another individual designated by AVITA Medical as a Designated Person (as described under Pre-Clearance Of Dealings by Designated Persons), before trading in AVITA Medical's securities during the window period, directors, executive officers, and Designated Persons must also comply with the pre-clearance procedures discussed below.

## **PRE-CLEARANCE OF DEALINGS BY DESIGNATED PERSONS**

Designated Persons and their respective family members and other affiliated persons or entities must pre-clear any intended transaction in AVITA Medical securities with the General Counsel, including any transaction during any open window period, not less than two trading days before the date of the intended transaction. This notice must contain a complete description of the intended transaction (e.g., purchase, sale, gift, contribution), including the identity and number of AVITA Medical securities, and the date and the stock exchange on which the intended transaction is proposed to occur. If you are subject to the requirements of Section 16 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), you should also consider whether you have effected any non-exempt transactions

within the past six months or otherwise that must be reported on an appropriate Form 4 or Form 5. In addition, you should be prepared to comply with Rule 144 under the Securities Act of 1933, as amended, (“Securities Act”) and requirements to file Form 144 (see Section titled Additional Requirements on Certain Designated Persons, below).

Designated Persons can only conduct transactions if: (i) the General Counsel approves the specified transaction; and (ii) such person is not otherwise in possession of material non-public information. If the General Counsel approves the intended transaction, such transaction must take place within the open window period following the approval (or such other period specified), at which time the transaction must comply with this Policy and applicable securities laws in all other respects. Subsequent confirmation of the transaction must be provided.

Clearance provided by the General Counsel does not constitute investment advice and if clearance is denied, the denial must be kept confidential and must not be disclosed to anyone.

For purposes of this Policy, “**Designated Persons**” include: (i) all directors of AVITA Medical; and (ii) employees of the Group who have been designated such by or on behalf of the General Counsel, including, without limitation, persons with the titles Chief Executive Officer, Chief Financial Officer, Chief Commercial Officer, Chief Operating Officer, Chief Technology Officer, General Counsel, Executive Vice President or Controller, as well as certain employees who work in accounting, finance, treasury, legal and compliance and investor relations roles within the Group. All Group employees who are classified as Designated Persons for purposes of this Policy will be notified of such classification by the General Counsel and will remain classified as a Designated Person until further notice. Additional employees may be temporarily subject to preclearance subject to their involvement in specific projects or events.

## **ADDITIONAL REQUIREMENTS ON CERTAIN DESIGNATED PERSONS**

If you are a director, an executive officer, or another reporting person under Section 16 of the Exchange Act (a “**Section 16 Individual**”) you must also comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16.

The practical effect of these provisions is that Section 16 Individuals who make “matching” transactions AVITA Medical’s securities within a six-month period (e.g., a purchase within six months prior to a sale, or a sale within six months prior to a purchase) must disgorge all profits from such transactions to AVITA Medical whether or not they had knowledge of any material nonpublic information and whether or not such transactions were pursuant to a 10b5-1 Plan.

The terms “purchase” and “sale” are construed under Section 16(b) to cover a broad range of transactions, including acquisitions and dispositions of shares in tender offers, the receipt and granting of certain options, the acquisition or sale of convertible debt and certain corporate restructurings and reorganizations. Purchases and sales by an insider may be matched with transactions by any person (such as certain family members and related or controlled corporations and entities) whose securities may be deemed to be beneficially owned by the insider. Section 16 rules define “beneficial ownership” as having or sharing a direct or indirect pecuniary interest in the securities (the opportunity directly or indirectly to profit or

share in the profit derived from a transaction in the securities). Certain transactions (i.e., those under AVITA Medical's equity incentive plan) may be exempted from Section 16(b).

If you are a Section 16 Individual, you must immediately report to the General Counsel and the Chief Financial Officer all transactions made in AVITA Medical's securities by you, any family members and any entities that you control subject to this Policy. AVITA Medical requires same-day reporting due to SEC requirements that certain insider reports be filed with the SEC by the second business day after the date on which a reportable transaction occurs. Contact the General Counsel for assistance with obtaining the required forms (generally Form 3, Form 4 or Form 5). Note that, although AVITA Medical is willing to assist Section 16 Individuals in meeting their Section 16 reporting obligations, it is ultimately the responsibility of the Section 16 Individual to comply with these requirements.

## **EXCEPTIONS FOR APPROVED RULE 10B5-1 PLANS**

Trades by Restricted Persons in AVITA Medical's securities that are executed pursuant to an approved Rule 10b5-1 Plan ("**10b5-1 Plan**") that meets the requirements of this Policy are not subject to the prohibition on trading on the basis of material nonpublic information contained in this Policy or to the restrictions set forth above relating to the trading window and pre-clearance procedures. Rule 10b5-1 provides an affirmative defense from insider trading liability under the federal securities laws for trading plans that meet certain requirements. In general, a 10b5-1 Plan must be entered into before a Restricted Person becomes aware of material nonpublic information. Once the 10b5-1 Plan is adopted, you must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The 10b5-1 Plan must either specify (including by formula) the amount, pricing and timing of transactions in advance or delegate discretion on those matters to an independent third party. AVITA Medical requires that each 10b5-1 Plan be entered into during an open window period when the Restricted Person is not in possession of material non-public information and for the first transaction to be effected under such 10b5-1 Plan not to occur for at least a month after the plan is entered into. All 10b5-1 Plans be approved in writing in advance by the General Counsel, and AVITA Medical reserves the right, in its sole discretion, to deny approval of any 10b5-1 Plan if AVITA Medical is of a view that the transactions contemplated by such plan would be in contravention of applicable law. Please be aware that there are many other considerations in proper use of a 10b5-1 Plan that are not covered by this Policy. For example, modifications of 10b5-1 Plans after they have been established or trading outside of a 10b5-1 Plan while it is in effect should be carefully considered.

## **ROLE OF THE GENERAL COUNSEL**

The General Counsel is responsible for administering this Policy and all determinations and interpretations of this Policy by the General Counsel are final and not subject to further review. The General Counsel will keep a record of all notifications of transactions supplied in accordance with this Policy. The General Counsel may appoint assistants for purposes of administering this Policy.

## **INDIVIDUAL RESPONSIBILITY**

You have an ethical and legal obligation to maintain the confidentiality of information about the Group and to not trade in AVITA Medical securities (or the securities of another company

or firm) while in possession of material non-public information. In all cases, the ultimate responsibility for adhering to this Policy and avoiding improper conduct rests with you, and any action on the part of the Group, the General Counsel or any other employee pursuant to this Policy does not in any way constitute legal advice or insulate you from liability under applicable securities laws. In the event of a violation of this Policy, AVITA Medical may take disciplinary action, including, but not limited to, declaring you ineligible for future participation in the Group's equity incentive plans, suspension or termination of your employment for cause. In addition, insider trading violations are aggressively pursued by relevant government agencies and violators may be subject to significant legal penalties, including criminal and civil fines and/or imprisonment, under applicable securities law. The same legal penalties apply to those who tip information even if they did not actually trade or benefit.

Applicable law may vary according to the jurisdiction in which the Group operates and where the applicable transaction occurs. The jurisdictions and applicable laws therein of significance to most persons covered by this Policy as of the date hereof, include (but may not be limited to):

- **Australia:** *Corporations Act 2001* (Cth): prohibited conduct by persons in possession of inside information (1043A), use of position and use of information (ss 182-183), market manipulation (ss1041A), and false or misleading statements (s 1041E); and
- **United States:** Securities Act of 1933, as amended; the Securities Exchange Act of 1934, as amended; the rules and regulations thereunder, and case law interpreting the same.

A summary of the insider trading laws and regulations in the United States and Australia applicable as of the date of this Policy are provided in the Appendices to this Policy. These laws may change over time or may be subject to new interpretations by relevant courts or administrative bodies. AVITA Medical undertakes no obligation to update the legal summaries attached to this Policy or to advise of changes relative to such laws and regulations. You are expected to keep yourself familiar with your legal obligations and to fully comply with those obligations. You are encouraged to retain your own legal counsel in the event you have any question regarding the application of applicable law to your specific situation.

## **ACKNOWLEDGMENT OF RECEIPT AND UNDERSTANDING OF THIS POLICY**

All Designated Persons and others as determined by the General Counsel must certify that they have received a copy of this Policy and that they understand its contents. In addition, each Designated Person must inform their respective family members and other affiliated persons or entities of their obligations under this Policy.

## **LODGING POLICY WITH GOVERNMENT AGENCY**

This Policy will be lodged with any government agency where the law in that particular jurisdiction requires it.

## Appendix 1

### AUSTRALIAN LAWS

The following summary is intended to provide you with an overview of applicable Australian securities laws and to highlight important requirements. The law in this area is complex and this Appendix does not cover every issue or situation. You should consult your own legal counsel as issues arise, and you should make yourself familiar with applicable legal requirements and with the requirements of the AVITA Medical Insider Trading and Securities Dealing Policy (“**Policy**”). In addition, you may wish to obtain your own legal advice or financial advice before you trade in securities. As used in this Appendix, AVITA Medical and its subsidiaries and affiliates are collectively referred to as the “**Company**”.

The Policy does not in any way limit your obligations under applicable law. In addition, you are required to comply with all provisions of the Policy even if the laws of any applicable jurisdiction do not prevent you from acting in that way, or do not specifically require a certain provision of the Policy.

Should you have any questions regarding the information contained in this Appendix 1, please contact the General Counsel.

### INSIDER TRADING

Section 1043A of the *Corporations Act 2001* (Cth) (“**Corporations Act**”) prohibits insider trading. The section applies where a person is in possession of information and:

- the information is not generally available;
- a reasonable person would have expected that information to have a material effect on the price or value of a security if it was generally available;
- the person knew, or ought reasonably to have known, that the information was not generally available and if it were so, a reasonable person would expect it to affect the price or value of the security.

If the section applies, it is an offence for the person to:

- (a) whether as a principal or agent subscribe for, or enter into an agreement to subscribe for, purchase or sell, securities;
- (b) procure another person to subscribe for, purchase or sell securities; and
- (c) communicate information to another person with the knowledge that the person will or is likely to do (a) or (b).

For the purposes of section 1043A, information is “generally available” where the information is either readily observable, or made known in a manner that would bring it to the attention of people who commonly invest in securities of the kind whose price or value would be affected by the information.



Section 1043A of the Corporations Act does not require that the “insider” be “connected” with the company whose securities are traded. It is sufficient that the person has information that is not generally available and has undertaken one of the acts prescribed above.

The penalties for breach of the statutory prohibitions of the Corporations Act may result in:

- criminal liability – penalties include heavy fines and imprisonment of up to 10 years;
- civil liability – including being sued by another party or the Company for any loss as a result of illegal trading activities; and
- civil penalty provisions – the Australian Securities and Investments Commission may seek civil penalties against you personally and may even seek a court order that you be disqualified from managing a corporation.

## **PROHIBITION ON IMPROPER USE OF INFORMATION**

Use of information obtained as a director, officer or employee of the Company for the person’s own gain may breach duties of confidence and of good faith owed to the Company under Australian corporate law. Sections 182 and 183 of the Corporations Act prohibit directors, officers and employees of a corporation from making improper use of their position as a director, officer or employee or information gained by virtue of that position to gain directly or indirectly an advantage for him or herself or for any other person or to cause detriment to the Company. Contravention of sections 182 and 183 may render a director, officer or employee liable for a monetary penalty or imprisonment.

## **MARKET MANIPULATION**

Section 1041A of the Corporations Act prohibits certain transactions that have the effect of creating an artificial price or maintaining prices at an artificial level.

Section 1041B of the Corporations Act prohibits any action or omission which is calculated to create a false or misleading appearance of active trading in any securities on a stock market, or to create a false or misleading appearance concerning the market for or the price of such securities. The section prohibits certain conduct, including purchases or sales of securities which do not involve a change in the beneficial ownership of the securities, and which have an effect upon the market price of the securities.

## **FALSE OR MISLEADING STATEMENTS**

Section 1041E of the Corporations Act prohibits making a statement or disseminating information that is false in a material particular or materially misleading and is likely to induce the sale or purchase of or subscription for securities or to affect the market price of the securities where a person does not care whether the statement is true or false or knows or ought reasonably to have known that the statement or information was false in a material particular or materially misleading.

Section 1041F of the Corporations Act prohibits a person from inducing another person to deal in securities:

- by making or publishing a statement, promise or forecast if the person knows, or is reckless as to whether, the statement is misleading, false or deceptive; or
- by dishonest concealment of material facts; or
- by recording or storing information that the person knows to be false or misleading in a material particular or materially misleading, if:
  - the information is recorded or stored in, or by means of, a mechanical, electronic or other device; and
  - when the information was recorded or stored, the person had reasonable grounds for expecting that it would be available to the other person, or a class of persons that includes the other person.

## Appendix 2

### UNITED STATES LAWS

The following summary is intended to provide you with an overview of applicable United States federal securities laws and to highlight important requirements. The law in this area is complex and this Appendix does not cover every issue or situation. You should consult your own legal counsel as issues arise, and you should make yourself familiar with applicable legal requirements and with the requirements of the AVITA Medical Insider Trading and Securities Dealing Policy (“**Policy**”). In addition, you may wish to obtain your own legal advice or financial advice before you trade in securities. As used in this Appendix, AVITA Medical and its subsidiaries and affiliates are collectively referred to as the “**Company**”.

The Policy does not in any way limit your obligations under applicable law. In addition, you are required to comply with all provisions of the Policy even if the laws of any applicable jurisdiction do not prevent you from acting in that way, or do not specifically require a certain provision of the Policy.

Should you have any questions regarding the information contained in this Appendix 2, please contact the General Counsel.

### UNITED STATES FEDERAL ANTIFRAUD RULES

#### A. Nature of Liability

Rule 10b-5, promulgated under Section 10(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), makes it unlawful for any person, in connection with the purchase or sale of any security, to make any untrue statement of a material fact or omit to state any material fact which would be necessary to make the statement made, in the light of the circumstances under which it was made, not misleading. Rule 10b-5 is the primary source of the United States case law that prohibits “insider trading”.

Rule 10b-5 also imposes an affirmative duty upon individuals to refrain from buying, selling or otherwise trading in securities while in possession of material information which is not yet publicly disseminated (inside information).

Rule 10b-5 also prohibits conveying inside information to others and from suggesting that anyone purchase or sell any securities while aware of inside information. These practices, known as “tipping,” violate the United States securities laws and can result in the same civil and criminal penalties that apply to insider trading directly, even if the violator does not receive any money or derive any benefit from trades made by persons to whom the violator passed inside information.

The Policy applies to securities of AVITA Medical as well as to securities of other companies, such as the Company’s customers and suppliers or a firm with which the Company is negotiating a major transaction with respect to which you may have access to confidential information. Directors, officers and employees of the Company, certain consultants and contractors, or persons to whom they disclose inside information, should not trade for their own benefit or recommend trading in securities on the basis of inside information. The same guidelines should be observed by the immediate family and close associates of such persons.

Directors, officers and employees of the Company should keep in mind the following important considerations regarding insider trading:

- The insider trading rules apply to sales as well as purchases of Company securities.
- “Trading” in Company securities includes the purchase and sale of Company securities in public markets, sales of Company securities obtained through the exercise of employee stock options, the purchase and sale of puts, calls and options, or other derivative securities (rights that are exercisable for or have a value based on the Company's securities), making gifts of Company securities and using Company securities to secure a loan.
- Family members and close associates might be presumed to have an insider's knowledge.
- Violation of the insider trading laws could result in criminal and administrative penalties (including fines, disgorgement of profits and imprisonment), civil damages, injunctions and consent decrees. Litigation, of course, also is expensive, time consuming and potentially embarrassing for a company and the individuals involved.
- Transactions by insiders can violate securities laws even if no “inside information” is involved. Transactions which manipulate the price of the Company's securities will also give rise to liability.
- There is no exception for small transactions or transactions that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency expenditure.

## **B. Insider Trading and Securities Fraud Enforcement Act**

Under the Insider Trading and Securities Fraud Enforcement Act of 1988 (ITSFEA), the Company and other controlling persons (which may be deemed to include directors and officers and the Company) who recklessly fail to prevent insider trading violations by employees, and the violator, may be held liable for civil penalties of up to the greater of about US\$1.5 million (subject to increase) or three times the profit realized or the losses avoided for each violation by a controlled person, and may be subject to criminal fines of up to US\$5 million and/or a jail sentence of up to 20 years. Both the violating controlled person and controlling persons may be held liable. In addition, the controlling person may also be held liable for violations by “tippers.” ITSFEA also provides a private cause of action to contemporaneous traders against the violator as well as his or her controlling persons. Both the Securities and Exchange Commission (SEC) and the Nasdaq are very effective at detecting and pursuing insider trading cases. The SEC has successfully prosecuted cases involving employees trading through foreign accounts, trading by family members and friends, and trading only a small number of shares.

## **LIMITATION ON PUBLIC SALES OF COMPANY SECURITIES BY DIRECTORS, OFFICERS AND OTHER DESIGNATED PERSONS**

Rule 144 under the Securities Act of 1933, as amended (the “**Securities Act**”), provides a means by which persons who might otherwise be required to register stock under the Securities Act prior to its public resale (those who might otherwise be considered to be “statutory underwriters” under the Securities Act) may resell their stock without registration. Two types of shareholders are covered: (a) those that hold “restricted securities” and (b) those that hold “control securities” and are deemed “affiliates” of the Company. Rule 144 compliance will be a part of the pre-clearance process discussed in the Policy.

#### **A. Definition of Affiliate**

An affiliate is defined as a person who directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the issuer of securities. In general, directors, executive officers and significant shareholders who have the power to influence or affect corporate affairs of the Company are “affiliates” of the Company. The SEC has defined control as direct or indirect power to direct or cause the direction of the management and policies of a person, whether through ownership of voting securities, by contract or otherwise. Control is dependent upon the circumstances of each case.

#### **B. Definition of Restricted Securities and Control Securities**

In general, “**restricted securities**” as defined in Rule 144 are securities acquired directly or indirectly from the Company or from an affiliate of the Company in a transaction or chain of transactions not involving any public offering (i.e., not acquired in a transaction registered with the SEC). Even where restricted securities are not involved, an affiliate must still comply with Rule 144 when selling securities acquired upon exercise of these stock options or otherwise.

“**Control securities**” are securities held by an affiliate of the issuing company.

#### **C. Application of Rule 144**

Unless their resale is registered with the SEC or some other exemption applies, the resale of control securities is always subject to restrictions under Rule 144. The maximum amount of control securities that may be sold in any three month period by an affiliate of the Company pursuant to Rule 144 is the greater of (i) 1% of all outstanding shares of the applicable class of Company securities or (ii) the average weekly trading volume for such Company securities during the four calendar weeks preceding the proposed sale.

The volume limitations apply to the sum of sales by the shareholder personally plus sales by members of such person's household and minor children and sales by entities in which the shareholder holds a ten percent or more equity interest.

Rule 144 generally permits shareholders who are not affiliates of the Company, however, to resell their restricted securities free from Rule 144 requirements after a six-month holding period has been satisfied.

Other important restrictions applicable to an affiliate selling control securities exist as to the manner of offering and as to the filing of an appropriate notice with the SEC, and all of these must be carefully evaluated in considering the use of Rule 144 to provide a resale exemption in each individual situation.

In the case of securities acquired upon the exercise of stock options, the holding period does not commence until exercise of the option.

Before making sales of Company securities, affiliates (who own control securities) and those who think they may own restricted stock should discuss the proposed transaction with counsel.